← Russell 3000 cross-section

ALMS ALUMIS INC.

Trailing twelve months to 2026-06-30 · as filed 2026-08-13, not restated
Healthcare

Scale

Market cap
$3.1bn
Revenue TTM
$7m
Net income TTM
$-439m
Free cash flow
$-352m
Composite score
Sector rank
#1382

Valuation

P / E
EV / EBITDA
EV / sales
410.6
FCF yield
-11.34%
Earnings yield vs 10-yr
-18.89pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-5,933.4%
EBITDA margin
-6,156.7%
ROE
-97.1%
ROIC
-118.2%
Revenue growth

Insider activity, last 90 days

Net open-market
$-0.53m
Buyers
0
Sellers
6

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

We will remain an emerging growth company until the earliest of: (i) the end of the fiscal year in which we have a total annual gross revenue of $1.235 billion; (ii) the last day of our fiscal year following the fifth anniversary of the completion of our IPO; (iii) the date on which we have, during the previous three-year period, issued more than $1.0 billion in non-convertible debt; or (iv) the end of the fiscal year in which the market value of common stock held by non-affiliates exceeds $700 million as of the prior June 30. …ALUMIS INC., 10-Q, period ended 2026-06-30, filed 2026-08-13

Read the full passage →